Phase I study of AR-42 and decitabine in acute myeloid leukemia

This phase I trial sought to determine a biologically safe and effective dose of AR-42, a novel histone deacetylase inhibitor, which would lead to a doubling of miR-29b prior to decitabine administration. Thirteen patients with previously untreated or relapsed/refractory AML were treated at 3 dose l...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Leuk Lymphoma
Autors principals: Liva, Sophia G., Coss, Christopher C., Wang, Jiang, Blum, William, Klisovic, Rebecca, Bhatnagar, Bhavana, Walsh, Katherine, Geyer, Susan, Zhao, Qiuhong, Garzon, Ramiro, Marcucci, Guido, Phelps, Mitch A., Walker, Alison R.
Format: Artigo
Idioma:Inglês
Publicat: 2020
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7375689/
https://ncbi.nlm.nih.gov/pubmed/32037935
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10428194.2020.1719095
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars